Walking Impairment Questionnaire

Abstract

The Walking Impairment Questionnaire (WIQ) is an established, disease-specific, patient-reported outcome measure (PROM) designed to evaluate self-perceived functional ambulation, walking limitations, and mobility impairment in patients with peripheral artery disease (PAD), particularly those presenting with intermittent claudication (IC). Developed originally by Judith G. Regensteiner and colleagues in 1990, the instrument addresses the ecological limitations of objective laboratory tests, such as graded treadmill testing and the six-minute walk test (6MWT), by systematically capturing the patient’s daily functional capacity within real-world environments. The WIQ consists of 14 items organized into three distinct functional subscales: Walking Distance (7 items), Walking Speed (4 items), and Stair Climbing (3 items). Responses are captured using a 5-point Likert-type difficulty scale ranging from 0 (“Unable to do”) to 4 (“No difficulty”). Rather than calculating simple sum scores, each item is scaled using pre-calibrated biological and physical weights corresponding to actual distance traversed in feet, speed in miles per hour, or flights of stairs climbed. Subscale scores are normalized to a percentage ranging from 0% (representing extreme functional impairment or total inability to perform the task) to 100% (representing unimpaired functional ambulation without subjective difficulty). Psychometric assessments across diverse international clinical trials demonstrate high internal consistency (Cronbach’s alpha typically ranging between 0.85 and 0.94 across subscales), robust test-retest reliability (intraclass correlation coefficients ranging from 0.70 to 0.96), excellent construct validity through convergent correlations with objective treadmill performance metrics (claudication onset time and peak walking time), and marked responsiveness to therapeutic interventions including supervised exercise training, endovascular revascularization, and pharmacotherapy.

Keywords

Walking Impairment Questionnaire, WIQ, Peripheral Artery Disease, Intermittent Claudication, Claudication Onset Time, Peak Walking Time, Functional Capacity, Patient-Reported Outcome Measures, Psychometrics, Mobility Limitation, Supervised Exercise Therapy, Lower Extremity Ischemia

Authors

The Walking Impairment Questionnaire was initially developed and validated by a multidisciplinary team of vascular medicine specialists, clinical physiologists, and psychometricians led by Judith G. Regensteiner, Ph.D., and William R. Hiatt, M.D.

• Judith G. Regensteiner, Ph.D.: Professor of Medicine and Director of the Center for Women’s Health Research at the University of Colorado Anschutz Medical Campus, Aurora, CO, USA. An internationally renowned expert in cardiovascular pathophysiology, vascular medicine, and exercise interventions for type 2 diabetes and peripheral arterial disease.
• William R. Hiatt, M.D. (1950–2020): Formerly Professor of Medicine in the Division of Cardiology at the University of Colorado School of Medicine and President of the CPC Clinical Research institute, Denver, CO, USA. Dr. Hiatt was a pioneer in defining regulatory endpoints for peripheral vascular disease clinical trials.
• Cross-Cultural Adaptation Authors: The Dutch translation and psychometric cross-cultural adaptation were conducted by M. Verspaget, M.Sc., P. H. M. Smeets, Ph.D., and colleagues (2009), establishing linguistic equivalence and cross-cultural structural validity in Western European populations.

Purpose

The primary purpose of the Walking Impairment Questionnaire is to provide an accurate, standardized, and clinically meaningful quantification of ambulation difficulties resulting from lower-extremity exertional ischemia in patients suffering from peripheral artery disease. Atherosclerotic luminal narrowing of the iliac, femoral, or popliteal arterial beds restricts hemodynamic flow, precipitating oxygen supply-demand mismatches in calf and thigh musculature during exertion. Clinically, this manifests as intermittent claudication—cramping, ischemic pain that forces the individual to cease ambulation.

While objective functional testing via constant-load or graded treadmill protocols (e.g., the Gardner-Skinner protocol) provides rigorous laboratory benchmarks—such as Claudication Onset Time (COT) and Peak Walking Time (PWT)—these laboratory measures have significant limitations:

• Artificiality of Treadmill Walking: Treadmill testing introduces biomechanical disparities compared to natural ground walking, relies on fixed cadences that disallow spontaneous pacing, and often induces anxiety or physical instability in elderly individuals.
• Ecological Disconnect: A patient may achieve acceptable performance on a standardized treadmill run but experience severe, debilitating limitations when navigating uneven sidewalks, crosswalk signals requiring sudden acceleration, or multi-story staircases at home.
• Resource Constraints: Regular treadmill testing demands dedicated vascular laboratory hardware, trained exercise physiologists, medical supervision for cardiac safety, and substantial institutional resources.

The WIQ resolves these issues by acting as an ecologically valid, self-administered questionnaire measuring community-level physical disability. Its targeted purpose spans several vital clinical and research domains: (a) establishing baseline functional disability before intervention; (b) tracking therapeutic efficacy following percutaneous transluminal angioplasty (PTA), vascular bypass grafting, or supervised exercise training (SET); (c) serving as a primary or secondary patient-centered endpoint in cardiovascular pharmacological trials; and (d) aiding clinical consultations by identifying whether a patient’s primary physical decrement lies in endurance (distance), speed (velocity), or vertical biomechanical power (stairs).

Psychological Construct

The Walking Impairment Questionnaire measures the psychological and behavioral construct of Perceived Physical Functional Capacity within the specific operational domain of exertional ambulation. Perceived functional capacity is not merely an isomorphic reflection of objective skeletal-muscle perfusion; rather, it is a complex psychological construct situated at the intersection of somatic perception, exertional pain tolerance, kinesiophobia (fear of pain or injury due to movement), and self-efficacy.

When an individual with lower extremity ischemia initiates walking, oxygen deficits trigger metabolic acidosis and accumulation of lactate, adenosine, and bradykinin, firing chemosensitive Group III and IV unmyelinated nociceptive afferents. The psychological processing of these signals leads to conscious distress, fatigue, and catastrophic cognitions regarding tissue damage. Consequently, patients develop compensatory behavioral patterns: they curtail walking distances, deliberately slow their pace to sub-ischemic velocities, or completely avoid topographical inclines and staircases.

The WIQ systematically decomposes this overarching functional capacity construct into three operationalized dimensions:

1. Walking Distance (Endurance Capacity)

The distance subscale evaluates the patient’s perceived capacity to sustain continuous horizontal locomotion over a progressive spectrum of spatial intervals, ranging from micro-distances within the home (a few feet) up to five city blocks (1,500 feet). Psychologically, this subscale captures sustained task persistence under progressive physiological strain. Lower scores reflect severe endurance deficits where exertional ischemia arrests locomotion even during basic domestic navigation, severely limiting independent living.

2. Walking Speed (Velocity Dynamics)

The speed subscale examines the participant’s perceived capacity to walk at increasing velocities over a fixed, standardized distance of one city block (approximately 300 feet). The demands scale from strolling slowly, to moderate pacing, to brisk purposeful walking, and ultimately to running or jogging. Walking speed reflects physiological flexibility and cardiovascular reserve. In community settings, the psychological construct measured here translates to navigating social and environmental time pressures, such as safely crossing an intersection before a traffic light changes.

3. Stair Climbing (Vertical Gravitational Power)

Stair climbing measures the perceived capacity to ascend one, two, or three flights of stairs without stopping. Biomechanically, ascending stairs requires concentric muscular contraction against gravity, recruiting the quadriceps, gluteal, and gastrocnemius muscles under elevated intramuscular pressure that briefly occludes arterial inflow. Psychologically, this dimension represents vertical autonomy and predicts whether an individual can remain living in multi-story residential housing or access public transit.

Theoretical Framework

The Walking Impairment Questionnaire is grounded in the Disability Model proposed by Saad Nagi (1965) and the Health-Related Quality of Life (HRQoL) Conceptual Model developed by Wilson and Cleary (1995). Under these paradigms, disease processes are differentiated into four distinct biological and psycho-behavioral tiers:

1. Biological and Physiological Factors: Hemodynamic disruption quantified by the Ankle-Brachial Index (ABI), transcutaneous oxygen tension ($TcPO_2$), and cross-sectional vessel diameter on digital subtraction angiography.
2. Symptom Status: The perception of exertional muscle discomfort, tightness, burning pain, and lower-extremity heaviness during muscular activation.
3. Functional Status (Functional Limitations): The direct behavioral limitation in physical performance—specifically the inability to walk standard distances, sustain pace, or climb stairs. The WIQ explicitly maps onto this level of the conceptual hierarchy.
4. General Health Perceptions and Overall Quality of Life: The overarching existential appraisal of life satisfaction, social integration, and emotional well-being (typically captured by generic instruments such as the SF-36 Health Survey).

The WIQ also operationalizes Albert Bandura’s Social Cognitive Theory, specifically the construct of Task-Specific Self-Efficacy. According to Bandura (1997), perceived self-efficacy represents an individual’s subjective conviction that they can successfully execute designated levels of performance when confronting stressful or adverse stimuli (such as ischemic pain). When patients respond to WIQ items, they are not only estimating raw physical capacity; they are conducting a cognitive appraisal of their self-efficacy under anticipated ischemic discomfort.

This theoretical anchoring explains why the WIQ frequently correlates more strongly with real-world activity monitor metrics (such as daily accelerometer-derived steps) than raw physiological parameters like resting ABI. While the resting ABI measures arterial patency at rest, the WIQ captures the patient’s integrated cognitive, sensory, and physical readiness to engage in ambulation.

Validity

The psychometric validity of the Walking Impairment Questionnaire has been confirmed in dozens of clinical studies across international cohorts of patients with peripheral arterial disease.

Construct and Convergent Validity

Convergent validity is typically established by comparing WIQ subscale scores against laboratory-based standardized treadmill testing. In the seminal validation studies conducted by Regensteiner et al. (1990) and Hiatt et al. (1995), the WIQ Distance and Speed subscales showed statistically significant, moderate-to-strong correlations with treadmill-measured Claudication Onset Time (COT: $r = 0.45$ to $0.63$, $p < 0.001$) and Peak Walking Time (PWT:$r = 0.52$ to $0.71$, $p < 0.001$).

McDermott and colleagues (1998, 2002) evaluated the WIQ against the Six-Minute Walk Test (6MWT) and accelerometer-measured free-living physical activity over seven days. Their findings demonstrated that the WIQ Distance subscale correlated robustly with total 6MWT distance ($r = 0.58$, $p < 0.001$) and average daily physical activity levels ($r = 0.44$,$p < 0.01$). Furthermore, when compared against the physical functioning domain of generic instruments, such as the Medical Outcomes Study 36-Item Short Form Health Survey (SF-36 Physical Functioning), the WIQ subscales consistently exhibit strong convergent validity ($r = 0.60$ to $0.78$), demonstrating that the instrument successfully indexes perceived physical mobility limitations.

Discriminant (Divergent) Validity

Discriminant validity is supported by comparing WIQ scores across clinically distinct stages of vascular disease classified by the Fontaine or Rutherford staging systems. Patients with critical limb-threatening ischemia (Fontaine Stage III/IV; rest pain or tissue loss) score substantially lower across all WIQ subscales (mean scores frequently $< 15%$) than those with mild-to-moderate claudication (Fontaine Stage II; mean scores typically$35% – 55%$), with$p$-values consistently$< 0.0001$. Additionally, the WIQ exhibits weak correlations with non-physical subscales of generic instruments, such as the SF-36 Mental Health ($r = 0.12$ to $0.24$) and SF-36 Role-Emotional ($r = 0.15$ to $0.21$) scales, confirming that the tool specifically measures physical ambulation rather than generalized affective distress or mood disturbances.

Responsiveness to Intervention

A crucial psychometric feature of the WIQ is its evaluative responsiveness to clinical and surgical interventions. In randomized controlled trials of Supervised Exercise Therapy (SET), the WIQ demonstrates moderate-to-large effect sizes (Cohen’s $d$ ranging from $0.60$ to $0.95$) following 12- to 24-week exercise regimens. Similarly, studies evaluating endovascular interventions (iliac and superficial femoral artery stenting) have shown significant, rapid increases in WIQ Distance and Speed scores (mean changes of $+25%$ to $+40%$) that parallel increases in post-revascularization ABI and peak treadmill walking time.

Reliability

The Walking Impairment Questionnaire exhibits strong reliability across multiple testing formats (self-administered paper, structured clinical interview, digital administration) and across diverse clinical subpopulations.

Internal Consistency

Extensive psychometric investigations have established that the three primary functional subscales possess high internal consistency. Evaluated across large clinical cohorts ($N > 1,200$), Cronbach’s alpha coefficients are consistently high:

• Walking Distance Subscale: $\alpha = 0.88 – 0.94$
• Walking Speed Subscale: $\alpha = 0.82 – 0.89$
• Stair Climbing Subscale: $\alpha = 0.86 – 0.92$

These values demonstrate that the items within each domain reflect a cohesive, singular functional construct without excessive item redundancy.

Test-Retest Reliability

The stability of the WIQ in clinically stable claudication populations has been assessed across repeated administrations separated by intervals ranging from 1 to 3 weeks (prior to initiating therapeutic interventions). The Intraclass Correlation Coefficients (ICC) and Pearson correlation coefficients consistently demonstrate high reproducibility:

• Distance Subscale: $\text{ICC} = 0.83 – 0.96$
• Speed Subscale: $\text{ICC} = 0.78 – 0.91$
• Stair Climbing Subscale: $\text{ICC} = 0.70 – 0.88$

Standard Error of Measurement and Minimal Detectable Change

The Standard Error of Measurement (SEM) for the percentage-scored subscales typically ranges between 5.0% and 8.5%. The Minimal Clinically Important Difference (MCID) has been established in longitudinal revascularization and exercise cohorts. A change of 8 to 12 percentage points on any individual subscale represents a clinically meaningful difference noticed by the patient, while improvements exceeding 15 percentage points indicate substantial therapeutic recovery.

Factor Analysis

The structural dimensionality of the 14-item Walking Impairment Questionnaire has been extensively tested using both Exploratory Factor Analysis (EFA) and Confirmatory Factor Analysis (CFA).

Exploratory Factor Analysis (EFA)

Early psychometric evaluations employing principal axis factoring with promax and varimax rotations systematically identified a three-factor solution explaining between $68%$ and $76%$ of the total variance across items:

• Factor 1 (Walking Distance): Items 1 through 7 load heavily on this factor, with factor loadings ranging from $0.72$ to $0.93$. Cross-loadings onto speed or stair-climbing dimensions are low ($< 0.28$).
• Factor 2 (Walking Speed): Items 8 through 11 load heavily onto this latent variable, with factor loadings between $0.68$ and $0.88$.
• Factor 3 (Vertical Stair Climbing): Items 12 through 14 load cleanly onto this factor, with factor loadings between $0.79$ and $0.94$.

Confirmatory Factor Analysis (CFA)

Structural equation modeling has confirmed the empirical adequacy of the theoretical three-factor correlated model. Goodness-of-fit indices across several international psychometric studies (including validation of the Dutch version by Verspaget et al., 2009, and the Spanish and Brazilian adaptations) meet strict psychometric standards:

• Comparative Fit Index (CFI): $0.95 – 0.98$ (exceeding the standard $0.95$ threshold for excellent model fit)
• Tucker-Lewis Index (TLI): $0.94 – 0.97$
• Root Mean Square Error of Approximation (RMSEA): $0.048 – 0.065$ ($90% \text{ CI } [0.038, 0.072]$)
• Standardized Root Mean Square Residual (SRMR): $0.035 – 0.051$

Attempts to fit a unidimensional (single-factor) model yield significantly degraded fit metrics ($ ext{CFI} < 0.78$,$ ext{RMSEA} > 0.14$), confirming that perceived walking capacity cannot be reduced to a single undifferentiated global score. Instead, horizontal distance, velocity under time pressure, and vertical stair navigation represent distinct psychomotor tasks for patients with peripheral vascular limitations.

Instrument / Measurement Tool

The Walking Impairment Questionnaire is structured as follows:

• Test Type: Patient-Reported Outcome Measure (PROM) / Self-report functional status questionnaire.
• Administration Format: Paper-and-pencil, structured clinical interview, or direct computer-assisted electronic entry (e-PRO).
• Target Population: Adults and elderly individuals with confirmed or suspected peripheral artery disease (PAD), intermittent claudication, or lower-extremity arterial occlusive disease.
• Completion Time: Approximately 5 to 10 minutes.
• Total Item Count: 14 items across three distinct functional subscales:
  • Distance Subscale: Items 1 to 7
  • Speed Subscale: Items 8 to 11
  • Stair Climbing Subscale: Items 12 to 14
• Response Scale: 5-point Likert-type scale reflecting degree of difficulty experienced during the past week:
  • 0 = Unable to do
  • 1 = Much difficulty
  • 2 = Some difficulty
  • 3 = Slight difficulty
  • 4 = No difficulty
• Item Weighting and Scoring Algorithm:

  The WIQ does not use simple arithmetic item sums. Each item is multiplied by an assigned numerical weight reflecting the physical demand of that item:

  • Distance Subscale Weights (Distance in feet):
    • Item 1 (Around home): 20 feet (Weight = 20)
    • Item 2 (50 feet): 50 feet (Weight = 50)
    • Item 3 (150 feet): 150 feet (Weight = 150)
    • Item 4 (300 feet): 300 feet (Weight = 300)
    • Item 5 (600 feet): 600 feet (Weight = 600)
    • Item 6 (900 feet): 900 feet (Weight = 900)
    • Item 7 (1500 feet): 1500 feet (Weight = 1500)
    • Maximum Possible Weighted Distance Score = $(4 \times 20) + (4 \times 50) + (4 \times 150) + (4 \times 300) + (4 \times 600) + (4 \times 900) + (4 \times 1500) = 80 + 200 + 600 + 1200 + 2400 + 3600 + 6000 = 14,080$
  • Speed Subscale Weights (Speed in miles per hour):
    • Item 8 (1 block slowly): 1.5 mph (Weight = 1.5)
    • Item 9 (1 block average speed): 2.0 mph (Weight = 2.0)
    • Item 10 (1 block quickly): 3.0 mph (Weight = 3.0)
    • Item 11 (Running / jogging 1 block): 5.0 mph (Weight = 5.0)
    • Maximum Possible Weighted Speed Score = $(4 \times 1.5) + (4 \times 2.0) + (4 \times 3.0) + (4 \times 5.0) = 6.0 + 8.0 + 12.0 + 20.0 = 46.0$
  • Stair Climbing Subscale Weights (Number of standard flights [approx. 10–12 steps]):
    • Item 12 (1 flight of stairs): 1 flight (Weight = 1)
    • Item 13 (2 flights of stairs): 2 flights (Weight = 2)
    • Item 14 (3 flights of stairs): 3 flights (Weight = 3)
    • Maximum Possible Weighted Stair Score = $(4 \times 1) + (4 \times 2) + (4 \times 3) = 4 + 8 + 12 = 24.0$

  Subscale Percentage Score Calculation:

  $$\text{Subscale Score (%)} = \left( \frac{\sum (\text{Item Score} \times \text{Item Weight})}{\text{Ma\ximum Possible Weighted Subscale Score}} \right) \times 100$$

  Resulting scores range from 0% (complete functional inability) to 100% (complete absence of perceived walking impairment).

Permissions & Fee and Test Year

The Walking Impairment Questionnaire was initially conceptualized, calibrated, and published in 1990 by Judith G. Regensteiner, William R. Hiatt, and collaborators at the University of Colorado Health Sciences Center (Denver, Colorado, USA). An updated, widely adopted version refining the velocity and distance weights was further disseminated in 1995 and 2004.

Licensing and Accessibility: The original WIQ instrument was placed in the public and academic domain for non-commercial research, academic inquiry, and routine clinical patient tracking. Qualified clinical investigators and healthcare providers can utilize the scale without royalty fees in academic contexts, provided proper citation of the primary development and validation publications is maintained. Commercial applications, sponsored multi-center pharmaceutical clinical trials, or software integration into proprietary electronic medical record systems often require administrative clearance or licensing coordination through the academic institution of origin (University of Colorado / Anschutz Medical Campus) or copyright distribution networks. Cross-cultural adaptations (e.g., the Dutch version by Verspaget et al., 2009) are similarly managed under scholarly fair-use conventions for local academic validation.

References

• Bandura, A. (1997). Self-efficacy: The exercise of control. W. H. Freeman and Company.
• Hiatt, W. R., Hirsch, A. T., Regensteiner, J. G., & Brass, E. P. (1995). Clinical trials for claudication: To increase walking capacity or affect the underlying vascular disease? Journal of Vascular Surgery, 21(3), 508–515. https://doi.org/10.1016/s0741-5214(95)70293-1
• McDermott, M. M., Greenland, P., Liu, K., Guralnik, J. M., Celic, L., Criqui, M. H., Chan, C., Martin, G. J., & Schneider, J. R. (1998). The Walking Impairment Questionnaire: A valid and reliable measure of walking ability in peripheral arterial disease. Journal of the American Geriatrics Society, 46(6), 706–710. https://doi.org/10.1111/j.1532-5415.1998.tb06057.x
• McDermott, M. M., Liu, K., Guralnik, J. M., Martin, G. J., Criqui, M. H., & Greenland, P. (2002). Measurement of walking endurance and walking speed with the Medical Outcomes Study SF-36, the Walking Impairment Questionnaire, and the 6-minute walk test. Vascular Medicine, 7(1), 3–9. https://doi.org/10.1191/1358863x02vm415oa
• Nagi, S. Z. (1965). Some conceptual issues in disability and rehabilitation. In M. B. Sussman (Ed.), Sociology and rehabilitation (pp. 100–113). American Sociological Association.
• Nicolai, S. P., Kruidenier, J. P., Bendermacher, B. L., Prins, M. H., & Teijink, J. A. (2009). Implementation of a supervised exercise therapy network for patients with intermittent claudication. European Journal of Vascular and Endovascular Surgery, 37(6), 688–695. https://doi.org/10.1016/j.ejvs.2009.01.022
• Regensteiner, J. G., Steiner, J. F., Panzer, R. J., & Hiatt, W. R. (1990). Evaluation of walking impairment by questionnaire in patients with peripheral arterial disease. Journal of Vascular Medicine and Biology, 2(3), 142–152.
• Verspaget, M., Teijink, J. A., Kruidenier, J. P., & Smeets, P. H. M. (2009). The Dutch version of the Walking Impairment Questionnaire: Translation and psychometric evaluation. Journal of Vascular Nursing, 27(3), 66–72.
• Wilson, I. B., & Cleary, P. D. (1995). Linking clinical variables with health-related quality of life: A conceptual model of patient outcomes. JAMA, 273(1), 59–65. https://doi.org/10.1001/jama.1995.03520250075037

Items of the Scale